PORTOS Validation in Phase 3 Trials: Gene Signature Predictor of Dose-Response to Prostate Radiation

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Shuang Zhao, MD, of the University of Wisconsin-Madison, discusses the PORTOS gene signature and its role in predicting radiation therapy dose response in prostate cancer. Dr. Zhao explains how PORTOS, developed on the Decipher platform, provides independent predictive insights into radiation therapy benefits beyond existing prognostic tools. The discussion covers its validation in clinical trials, potential integration into modern treatment approaches, and its incorporation into upcoming prospective studies.